Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 18OTHER 4NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Interventional × brivanib × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡